Joan Clària, head of the Inflammation on liver disease research group at IDIBAPS-Clínic, has been one of the winners of the Albus awards, given annually by the company Grifols. With an endowment of 50,000 euros, the award promotes research on albumin as a therapeutic product.
In the case of the group headed by Dr. Clària, the funding will be used to investigate the biological effects on cells of the innate immune system of albumin when it is present in its oxidized form, as in the case of patients with chronic liver disease. According to the hypothesis of the IDIBAPS group, the oxidized form of albumin could have an inflammatory effect which helps to exacerbate systemic inflammatory response in chronic liver disease patients and that often leads to multiple organ failure.
The award ceremony took place on 4 October in Milan
(Image: Dirk Michael Deckbar)